Novo Nordisk sues rival Eli Lilly over ‘misleading' weight-loss drug advertising
Headline from NBC 5 Dallas-Fort Worth
A Lilly Biotechnology Center in San Diego, California, and Novo Nordisk flags and logo displayed outside the company’s facility in Mainz, Germany.
NBC 5 Dallas-Fort Worth's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.
Novo Dordisk, which makes Ozempic and Wegovy, has filed a federal lawsuit against Eli Lilly, accusing its competitor of false advertising and unfair competition. Novo Nordisk challenges national ad campaigns from Eli Lilly that compare GLP-1 drugs from both companies, saying that Lilly intentionally…
Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing arch US rival Eli Lilly over "false and materially misleading" adverts for its competing weight-loss and anti-diabetes treatments.
Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effective Ozempic maker Novo Nordisk said on Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.
Drugmaker Novo Nordisk sued rival Eli Lilly on Tuesday, accusing the company of false advertising over the performance of its weight loss drugs. The lawsuit, filed in federal district court in New Jersey, alleges Lilly intentionally selected outdated studies to show the use of Mounjaro and Zepbound …
Novo is seeking to force Lilly to pull the disputed ads and run corrective ones as the companies compete for dominance in the booming obesity drug market.
Novo Nordisk filed a lawsuit against Eli Lilly & Co. accusing the manufacturer of Zepbound of deceptive advertising for allegedly comparing high doses of its drug to low doses of Wegovy.
